Waldencast plc Files Form 15 to Deregister its Securities and Suspend its SEC Reporting Obligations under the Exchange Act
Former L’Oréal execs set out to build a $1.2 billion beauty empire. Now all that’s left is Milk Makeup, and its sales just fell 57%
Waldencast plc Announces First Half 2026 Financial Results
Waldencast H1 EPS $(0.75) Misses $(0.13) Estimate, Sales $26.102M Miss $65.566M Estimate
Waldencast plc Files Form 25 to Voluntary Delist from Nasdaq and Deregister its Securities under the Exchange Act
Waldencast Files Form 25 With SEC To Voluntarily Delist Its Class A Ordinary Share, Effective Oct. 2
Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act
Waldencast To Voluntarily Delist Its Shares From The Nasdaq
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
Waldencast Receives FDA Approval For Obagi Saypha ChIQ Injectable Hyaluronic ACID Gel
Canaccord Genuity Maintains Buy on Waldencast, Raises Price Target to $3
Waldencast Announces Sale of Obagi Medical to Bridgepoint
Waldencast Sells Obagi Medical To Bridgepoint For Up To $460M
Obagi Medical Announces New Skincare And Filler Data At Nashville SCALE Meeting
How Waldencast (WALD) Story Is Shifting As Targets Fall And Brand Hopes Persist
Reported Earlier, Waldencast Announces SEC Concludes Investigation With No Enforcement Action Recommended Against The Company
Waldencast announces conclusion of SEC investigation
Waldencast's Obagi Medical Announces Collaboration With ProMD Health As Part Of Obagi's Hyaluronic Acid Program
Telsey Advisory Group Maintains Market Perform on Waldencast, Lowers Price Target to $2
Canaccord Genuity Maintains Buy on Waldencast, Lowers Price Target to $2
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.